PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24192124-3	2013	EGFR mutation as well as KRAS and ALK rearrangements are important biomarkers in the field owing to potential targeted therapies involved in clinical practice: erlotinib, geftinib, cetuximab and crizotinib.	Erlotinib Hydrochloride	160-169	ALK receptor tyrosine kinase	Homo sapiens	34-37